BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. HLVXa clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines, announced today that it will be attending the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVax’s investigational virus-like particle (VLP) vaccine for the prevention of moderate to severe norovirus-associated acute gastroenteritis, and the associated ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events.
| Guggenheim Fireside Chat Details: | ||
| Date: Time: Moderator: HilleVax participants: |
Monday 14 November 2022 3:55 p.m. – 4:20 p.m. Eastern Daylight Time (EDT) Seamus Fernandez Robert Hershberg, MD, Ph.D., Chairman and Chief Executive Officer |
|
| Please contact your Guggenheim representative to access the session | ||
| Details of the Stifel presentation: Date: Time: Moderator: HilleVax participants: Webcast Link: |
Wednesday 16 November 2022 8:35 a.m. – 9:05 a.m. Eastern Daylight Time (EDT) Stephen Willy Robert Hershberg, MD, Ph.D., Chairman and Chief Executive Officer https://wsw.com/webcast/stifel74/hlvx/2126052 |
|
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines. Its first program, HIL-214, is a virus-like particle (VLP)-based vaccine candidate under development to prevent moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. It is estimated that norovirus causes over approximately 700 million cases of AGE and 200,000 deaths worldwide each year, resulting in over US$4 billion in direct health care costs and US$60 billion in societal costs each year. The burden of norovirus falls disproportionately on young children and older adults. For more information on HilleVax, visit…
[ad_2]
Source story
